Systematic Review: Accuracy of Anti–Citrullinated Peptide Antibodies for Diagnosing Rheumatoid Arthritis

Whiting, Penny; Smidt, Nynke; Sterne, Jonathan A C; Harbord, Roger; Burton, Anya; Burke, M. Desmond; Beynon, Rebecca; Ben-Shlomo, Yoav; Axford, John S.; Dieppe, Paul

doi:10.7326/0003-4819-152-7-201004060-00010

Cited by 168 publications

(138 citation statements)

References 139 publications

Supporting

Mentioning

128

Contrasting

Unclassified

Order By: Relevance

“…The reported specificity for the anti-CCP test in the present study was 87.2%, which is a bit lower compared with previous studies (8). The reason for the lower specificity found in this study would be inclusion of patients with PsA as a control group (together with healthy controls), instead of constructing a more heterogeneous control group, with the inclusion of other forms of arthritis.…”

Section: In This Issue Ofcontrasting

confidence: 54%

The clinical utility of anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis

Şimşek

2014

Eur J Rheumatol

View full text Add to dashboard Cite

Section: In This Issue Ofcontrasting

confidence: 54%

The clinical utility of anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis

Şimşek

2014

Eur J Rheumatol

View full text Add to dashboard Cite

“…82 Up to 30% of RA patients never develop ACPA. 85 An association has been defined between the presence of circulating ACPA and subsequent development of RA in subjects with arthralgia, 87 and with bone erosions in early untreated subjects. 88 Delay in diagnosis of RA may arise from either a lack of a definitive biomarker, or a failure to meet current diagnostic criteria, and these criteria have a significant reliance on biomarkers.…”

Section: Early Arthritis and Early Diagnosismentioning

confidence: 99%

Synovial tissue research: a state-of-the-art review

et al. 2017

View full text Add to dashboard Cite

The synovium is the major target tissue of inflammatory arthritides such as rheumatoid arthritis (RA). The study of synovial tissue has advanced significantly over a number of decades from arthroplasty, blind needle biopsy and more recently facilitated by arthroscopic and ultrasonographic technology that allows easier visualisation and improves the reliability of obtaining synovial biopsies. The potential for study of pathogenesis, patient stratification, discovery of biomarkers and novel targets, as well as validation of therapy, have all been progressed rapidly in the last decade, facilitated by increasingly diverse and sophisticated analytical and technological approaches. In this review we describe clinical and translational developments in the field of synovial tissue research, outlining current and novel investigative technologies, and highlight their application to advance our understanding of the aforegoing imperatives.3

show abstract

“…Moreover, a recent systematic review has been published on the accuracy of ACPA in diagnosing early RA. This analysis of 151 studies shows hat sensitivity and specificity are 57 and 96 %, respectively (analysis refers only to 15 relevant cohort studies) [13].…”

Section: The Usefulness Of Acpamentioning

confidence: 99%

The challenge of using the rheumatoid arthritis diagnostic criteria in clinical practice

Corrao

Argano

Calvo³

et al. 2015

Intern Emerg Med

View full text Add to dashboard Cite

The new 2010 ACR/EULAR (American College of Rheumatology/European League Against Rheumatism) criteria of Rheumatoid Arthritis recently published, have been released to classify and identify patients with early RA who could benefit from early therapy. They recommend anti-citrullinated protein antibody (ACPA) testing as an alternative criterion to Rheumatoid Factor (RF) and ACPA that were introduced together with the other classic criteria in a scoring system. We previously criticized these new criteria because of unavailable specificity and sensibility in the first paper, and the use of ACPA as dichotomous criterion (presence/absent) and alternatives to rheumatoid factor. Our previous work promoted discussion and fostered new research on this issue. By the light of new data, in an effort to improve clinical reasoning, we suggest a more practical probabilistic point of view. In this regard, we analyze the sensitivity and specificity of the diagnostic studies that evaluate the performance of the 2010 classification criteria. Then, we compare the old and the new classification criteria. Subsequently, we describe the use of likelihood ratios applied to the classification criteria and different cutoff levels of ACPA for decisionmaking in different setting. Moreover, we define some properties of likelihood ratios and their use for diagnosing or excluding rheumatoid arthritis. We want to share this kind of knowledge within the scientific community because we believe that it can help general practitioners and specialists to recognize early arthritis patients implementing a more efficient probabilistic clinical reasoning.

show abstract

Systematic Review: Accuracy of Anti–Citrullinated Peptide Antibodies for Diagnosing Rheumatoid Arthritis

Abstract: Anti-CCP2 should be included in the work-up of patients with early symptoms of rheumatoid arthritis.

Cited by 168 publications

References 139 publications

The clinical utility of anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis

The clinical utility of anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis

Synovial tissue research: a state-of-the-art review

The challenge of using the rheumatoid arthritis diagnostic criteria in clinical practice

Contact Info

Product

Resources

About